共 4 条
[1]
Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation
[J].
LIVER TRANSPLANTATION,
2003, 9 (02)
:182-187
Han, SH
;
Martin, P
;
Edelstein, M
;
Hu, R
;
Kunder, G
;
Holt, C
;
Saab, S
;
Durazo, F
;
Goldstein, L
;
Farmer, D
;
Ghobrial, RM
;
Busuttil, RW
.
[2]
Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation
[J].
TRANSPLANTATION PROCEEDINGS,
2003, 35 (02)
:723-724
Sousa, JM
;
Pareja, F
;
Serrano, J
;
Gómez, MA
;
García, I
;
Tamayo, MJ
;
Díaz, C
;
Martín, C
;
Pascasio, JM
;
Hinojosa, R
;
Pérez-Bernal, JB
;
Cañas, E
;
Sayago, M
;
Bernardos, A
.
[3]
Increasing applicability of liver transplantation for patients with hepatitis B–related liver disease.[J].Thomas Steinmüller;Daniel Seehofer;Nada Rayes;Andrea R. Müller;Utz Settmacher;Sven Jonas;Ruth Neuhaus;Thomas Berg;Uwe Hopf;Peter Neuhaus.Hepatology.2002, 6
[4]
A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.[J].Robert P. Perrillo;Teresa Wright;Jorge Rakela;Gary Levy;Eugene Schiff;Robert Gish;Paul Martin;Jules Dienstag;Paul Adams;Rolland Dickson;Gaya Anschuetz;Steve Bell;Lynn Condreay;Nathaniel Brown.Hepatology.2001, 2